- Home
- TELA
TELA
TELA Bio Inc.
as 06-20-2025 3:42pm EST
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 36.4M | IPO Year: | 2019 |
| Target Price: | $6.00 | AVG Volume (30 days): | 181.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.86 - $5.56 | Next Earning Date: | 08-11-2025 |
| Revenue: | $71,217,000 | Revenue Growth: | 12.78% |
| Revenue Growth (this year): | 26.67% | Revenue Growth (next year): | 22.63% |
Latest TELA Bio Inc. News
TELA Breaking Stock News: Dive into TELA Ticker-Specific Updates for Smart Investing
GuruFocus.com
14 days ago
Aroa Biosurgery Ltd (AROAF) (FY25) Earnings Call Highlights: Surpassing Revenue Expectations ...
GlobeNewswire
15 days ago
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
18 days ago
TELA Bio Launches Tissue Matrix in Europe for Inguinal Hernia Repair
GlobeNewswire
18 days ago
TELA Bio Announces European Commercial Launch of OviTex® Inguinal for Robotic and Laparoscopic Inguinal Hernia Repair
GlobeNewswire
19 days ago
TELA Bio Appoints Jeffrey Blizard as President
GlobeNewswire
a month ago
TELA Bio to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
a month ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
a month ago
TELA Bio Inc (TELA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Challenges
Compare TELA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TELA TELA Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.